

---

# Does Regularizing Fluoxetine Intake Time Improve Depression Symptoms? A Single-Subject Study

---

Anonymous Author(s)

Affiliation

Address

email

## Abstract

We evaluated whether taking fluoxetine at a more consistent clock time improves depression symptoms for a single 35-year-old male with diagnosed depression, autism spectrum disorder and ADHD. The subject recorded multiple daily mood (1-5) and energy (1-5) ratings, daily fluoxetine 60 mg intake timestamps and weekly BDI-II scores. Two phases were analyzed in Europe/Berlin time: irregular intake (2025-03-17 to 2025-03-31) and regularized intake (2025-04-01 to 2025-05-15). Primary outcomes were daily median mood and energy on days with a recorded dose. Intake regularity increased (circular SD 0.87 vs 0.39 rad; difference 0.48 rad, 95% CI [-0.15, 1.14]). Contrary to the hypothesis, daily mood was lower during regularization (mean difference -0.46; Hedges g -0.59, 95% CI [-1.68, 0.30]; permutation p=0.095). Daily energy showed little change (difference -0.08; g -0.11, 95% CI [-0.77, 0.47]; p=0.809). Exploratory BDI-II increased from 27.0 to 30.8 (mean difference +3.8). This single-subject observational design limits causal inference; findings suggest intake-time regularization alone did not improve symptoms over these dates.

## 1 Introduction

Antidepressant timing advice commonly emphasizes taking medication at the same time each day, but empirical evidence for timing regularity improving outcomes is limited in the context of selective serotonin reuptake inhibitors such as fluoxetine. We analyze whether moving from irregular to regular clock-time intake is associated with improved symptoms in a single-subject observational study. The outcome measures are daily mood and energy ratings and weekly BDI-II scores collected between March and May 2025.

## 2 Methods

### 2.1 Hypotheses

We preregistered the following testable hypotheses for this single-subject observational study:

1. H1: Regularizing clock-time intake increases daily mood compared to the irregular baseline period.
2. H2: Regularizing clock-time intake increases daily energy compared to the irregular baseline period.
3. H3 (manipulation check): Intake time-of-day is more concentrated (lower circular SD) during the regularized period than during baseline.
4. H4: Greater deviation from the typical intake time associates with worse outcomes on the same day and the following day.

34 5. H5 (exploratory): BDI-II total decreases after 2025-04-01 relative to baseline.

35 **2.2 Design and data**

36 The subject is a 35-year-old male with diagnosed depression, autism spectrum disorder and ADHD.  
37 Fluoxetine 60 mg daily was continued throughout. Two phases were defined a priori: irregular intake  
38 between 2025-03-17 and 2025-03-31, then an attempt to take fluoxetine at a consistent time from  
39 2025-04-01 to 2025-05-15. The Android app logged medication timestamps, multiple mood and  
40 energy entries per day on 1-5 scales, and weekly BDI-II totals. Timestamps are naive but represent  
41 Europe/Berlin local time; we localized them with daylight-saving transitions.

42 **2.3 Preprocessing**

43 We localized timestamps to Europe/Berlin, derived calendar days, and labeled each day by phase. For  
44 primary analyses we aggregated outcomes per day as medians and restricted to days with a recorded  
45 fluoxetine dose. Intake time-of-day was mapped to angles on the circle to quantify regularity.

46 **2.4 Analyses**

47 Manipulation check: we computed circular mean time-of-day and circular standard deviation (SD)  
48 within each phase and used bootstrap to form a 95% CI for the SD difference (baseline minus  
49 regularized).  
50 Primary outcomes: phase effects on daily median mood and energy were summarized by mean  
51 differences, Hedges  $g$  with 95% bootstrap confidence intervals and permutation p-values.  
52 Secondary analyses: absolute circular deviation (minutes) from each phase-specific mean intake  
53 time was related to same-day and next-day outcomes using ordinary least squares with Newey-West  
54 standard errors and Spearman correlations.  
55 Exploratory: BDI-II means were compared pre/post with a bootstrap CI acknowledging small sample  
56 size.

57 **2.5 Computational details and hyperparameters**

58 To enable reproduction from the paper text alone, we state the exact settings used in all analyses.

- 59 • Time handling: timestamps are localized to Europe/Berlin; day boundary is 00:00–24:00  
60 local. Intake time-of-day is converted to minutes since midnight and then to angles  $\theta =$   
61  $2\pi$  minutes/1440.
- 62 • Inclusion for primary outcomes: days with a recorded fluoxetine dose and at least one mood  
63 and one energy entry. Outcomes per day are medians across entries.
- 64 • Manipulation check: circular SD per phase; Rayleigh test for non-uniformity. Bootstrap for  
65 SD difference uses  $B=5000$  resamples with replacement per phase.
- 66 • Phase contrasts (mood, energy): effect size is Hedges  $g$  computed on daily medians. CIs via  
67 bootstrap with  $B=5000$  paired resamples of the two phase samples. Permutation p-values  
68 use 10,000 label permutations of pooled daily medians.
- 69 • Deviation models: absolute circular deviation in minutes from the phase circular mean.  
70 Same-day and lag-1 models use OLS with Newey–West HAC standard errors (maxlags=3).  
71 Rank correlation is Spearman  $\rho$ .
- 72 • BDI-II: mean difference (post – pre) with bootstrap CI using  $B=5000$  resamples.
- 73 • Randomness: all resampling/permuation procedures use a fixed seed of 42.

74 **2.6 Software and reproducibility**

75 Analyses ran in a controlled, deterministic environment. Code produces PDF figures and machine-  
76 readable results. Exact commands and pins are documented and will be released with the repository  
77 after review. Figures mark the 2025-04-01 boundary.

Table 1: Per-phase summary. Values are means and medians of daily ratings (1-5). Dose days are days with a recorded dose; Outcome days are days with at least one mood and energy entry.

Phase	Dose days	Outcome days	Mood mean	Mood median	Energy mean	Energy median
Baseline	12	11	2.64	2.50	1.68	2.00
Regularized	44	39	2.18	2.00	1.60	1.50

### 78 3 Results

#### 79 3.1 Manipulation check

80 Intake timing became more regular during regularization: circular SD decreased from 0.87 rad  
 81 (baseline) to 0.39 rad (regularized); difference 0.48 rad (95% CI [-0.15, 1.14]). The Rayleigh test  
 82 indicated concentrated timing in both phases.

#### 83 3.2 Primary outcomes

84 Daily median mood was lower during regularization (baseline mean 2.64, regularized mean 2.18;  
 85 difference -0.46; Hedges g -0.59, 95% CI [-1.68, 0.30]; permutation p=0.095). Daily median energy  
 86 showed little change (baseline 1.68, regularized 1.60; difference -0.08; g -0.11, 95% CI [-0.77, 0.47];  
 87 p=0.809).

#### 88 3.3 Summary table

89 Table 1 summarizes per-phase days and daily outcome aggregates.

#### 90 3.4 Secondary and exploratory

91 Same-day absolute deviation from typical intake time showed a small positive association with mood  
 92 in HAC-OLS (slope 0.0025 per minute, p=1.9e-05) but not in rank correlation; next-day associations  
 93 were negligible. Weekly BDI-II was higher post 2025-04-01 (27.0 to 30.8; mean difference +3.8).

#### 94 3.5 Robustness

95 Controlling for weekday and a linear time trend in HAC-OLS yielded a phase coefficient near zero  
 96 for mood (beta -0.14, p=0.78) and for energy (beta 0.37, p=0.19), consistent with no beneficial effect  
 97 from regularization after accounting for routine. Using daily means instead of medians gave similar  
 98 conclusions: mood difference -0.64 (Hedges g -0.91, 95% CI [-1.99, -0.07]; permutation p=0.009),  
 99 energy difference -0.16 (g -0.27, 95% CI [-0.87, 0.26]; p=0.434).

### 100 4 Discussion

101 In this single-subject study, constraining fluoxetine intake to a more regular clock time did not improve  
 102 mood or energy on average over the observation window; estimates were compatible with no benefit  
 103 and suggested a possible decrease in mood. Intake timing clearly became more consistent, confirming  
 104 the manipulation. Observational design, limited sample size (especially for BDI-II), self-report  
 105 outcomes and potential confounding (sleep, seasonality, daily routine) limit causal interpretation.  
 106 The same-day positive HAC-OLS association between irregular timing and mood likely reflects  
 107 unmodeled diurnal or contextual effects; it was not robust in rank correlation. Results emphasize that  
 108 for this subject, timing regularity alone was insufficient to produce noticeable symptom changes over  
 109 these dates.

### 110 5 Conclusion

111 For this subject between 2025-03-17 and 2025-05-15, increasing the regularity of fluoxetine intake  
 112 time did not improve daily mood or energy, and BDI-II did not decrease. Future work could test  
 113 longer windows, different dosing times relative to wake, or designs that control sleep and routine.




Figure 1: Daily median mood and energy with phase shading. Baseline: 2025-03-17..2025-03-31. Regularized: 2025-04-01..2025-05-15.




Figure 2: Distribution of intake time-of-day by phase.

## 114 Broader Impact

115 N-of-1 analyses can help individuals evaluate treatment practices using their own data, but require  
 116 careful interpretation to avoid overgeneralization. Sharing anonymized data and exact code supports  
 117 transparency while respecting privacy.

## 118 Reproducibility Statement

119 We ran analyses deterministically with seeds set and generate figures as PDF. A step-by-step repro-  
 120 duction guide with exact commands and dependency pins will be released with the repository after  
 121 review.

122 **Availability Statement**

123 Upon acceptance we will release a Codeberg repository that meets open science standards, containing  
124 everything needed to reproduce this work: analysis code released as open source under the MIT  
125 license, an anonymized dataset released as open data under the ODC-By 1.0 license and manuscript  
126 text and figures under CC BY 4.0 International. The repository will include an exact step-by-step  
127 reproduction guide.

128 Links will be provided after review.

129 **Responsible AI Statement**

130 An AI agent served as the lead author under human oversight, executed analysis and wrote the  
131 manuscript following a reproducibility-first protocol. We disclose roles in the AI Involvement  
132 Checklist and release code and data for audit. No personally identifying information is included.

133 **Agents4Science AI Involvement Checklist**

- 134 1. **Hypothesis development:** Hypothesis development includes the process by which you  
135 came to explore this research topic and research question. This can involve the background  
136 research performed by either researchers or by AI. This can also involve whether the idea  
137 was proposed by researchers or by AI.

138 Answer: [C]

139 Explanation: The human advisor provided the research question and context; the AI agent  
140 proposed formal hypotheses aligned to the question and planned the analysis with conserva-  
141 tive defaults recorded in internal project notes.

- 142 2. **Experimental design and implementation:** This category includes design of experiments  
143 that are used to test the hypotheses, coding and implementation of computational methods,  
144 and the execution of these experiments.

145 Answer: [D]

146 Explanation: The AI agent implemented all data loading, preprocessing, analyses, statistics  
147 and figure generation; humans did not code.

- 148 3. **Analysis of data and interpretation of results:** This category encompasses any process to  
149 organize and process data for the experiments in the paper. It also includes interpretations of  
150 the results of the study.

151 Answer: [D]

152 Explanation: The AI agent analyzed outputs, reported effect sizes with uncertainty and  
153 interpreted findings with explicit limitations; the human provided high-level oversight only.

- 154 4. **Writing:** This includes any processes for compiling results, methods, etc. into the final  
155 paper form. This can involve not only writing of the main text but also figure-making,  
156 improving layout of the manuscript, and formulation of narrative.

157 Answer: [D]

158 Explanation: The AI agent wrote the manuscript sections and integrated figures, following  
159 the conference template and reproducibility requirements.

- 160 5. **Observed AI Limitations:** What limitations have you found when using AI as a partner or  
161 lead author?

162 Description: In this project I produced plausible analyses quickly but struggled with publica-  
163 tion workflow details. I needed extensive guidance to remove template examples/instructions,  
164 write a compliant abstract, and complete the checklists. Early drafts missed required items  
165 (e.g., hypotheses) and made avoidable LaTeX mistakes (e.g., unescaped percent signs).  
166 Using more of the context window increased forgetfulness of instructions (quality checks,  
167 updating notes). At times I asked questions answerable from available files. We mitigated  
168 these issues with a pre-specified plan, targeted robustness checks, structured QA scripts,  
169 and iterative advisor feedback. Going forward, a robust authoring skeleton (boilerplate,  
170 headings, required statements pre-laid out) and venue templates that minimize deletions  
171 would reduce failure modes and allow more focus on scientific work.

172 **Agents4Science Paper Checklist**

173 **1. Claims**

174 Question: Do the main claims made in the abstract and introduction accurately reflect the  
175 paper's contributions and scope?

176 Answer: [Yes]

177 Justification: The abstract and introduction match the methods and results, including dates,  
178 outcomes, effect sizes and limitations.

179 Guidelines:

- 180 • The answer NA means that the abstract and introduction do not include the claims  
181 made in the paper.  
182 • The abstract and/or introduction should clearly state the claims made, including the  
183 contributions made in the paper and important assumptions and limitations. A No or  
184 NA answer to this question will not be perceived well by the reviewers.  
185 • The claims made should match theoretical and experimental results, and reflect how  
186 much the results can be expected to generalize to other settings.  
187 • It is fine to include aspirational goals as motivation as long as it is clear that these goals  
188 are not attained by the paper.

189 **2. Limitations**

190 Question: Does the paper discuss the limitations of the work performed by the authors?

191 Answer: [Yes]

192 Justification: Discussion states observational design, sample size, self-report and confounding  
193 limits and avoids causal claims.

194 Guidelines:

- 195 • The answer NA means that the paper has no limitation while the answer No means that  
196 the paper has limitations, but those are not discussed in the paper.  
197 • The authors are encouraged to create a separate "Limitations" section in their paper.  
198 • The paper should point out any strong assumptions and how robust the results are to  
199 violations of these assumptions (e.g., independence assumptions, noiseless settings,  
200 model well-specification, asymptotic approximations only holding locally). The authors  
201 should reflect on how these assumptions might be violated in practice and what the  
202 implications would be.  
203 • The authors should reflect on the scope of the claims made, e.g., if the approach was  
204 only tested on a few datasets or with a few runs. In general, empirical results often  
205 depend on implicit assumptions, which should be articulated.  
206 • The authors should reflect on the factors that influence the performance of the approach.  
207 For example, a facial recognition algorithm may perform poorly when image resolution  
208 is low or images are taken in low lighting.  
209 • The authors should discuss the computational efficiency of the proposed algorithms  
210 and how they scale with dataset size.  
211 • If applicable, the authors should discuss possible limitations of their approach to  
212 address problems of privacy and fairness.  
213 • While the authors might fear that complete honesty about limitations might be used by  
214 reviewers as grounds for rejection, a worse outcome might be that reviewers discover  
215 limitations that aren't acknowledged in the paper. Reviewers will be specifically  
216 instructed to not penalize honesty concerning limitations.

217 **3. Theory assumptions and proofs**

218 Question: For each theoretical result, does the paper provide the full set of assumptions and  
219 a complete (and correct) proof?

220 Answer: [NA]

221 Justification: No theoretical results; the study is empirical and reports statistical assumptions  
222 only.

223 Guidelines:

- 224 • The answer NA means that the paper does not include theoretical results.  
225 • All the theorems, formulas, and proofs in the paper should be numbered and cross-  
226 referenced.  
227 • All assumptions should be clearly stated or referenced in the statement of any theorems.  
228 • The proofs can either appear in the main paper or the supplemental material, but if  
229 they appear in the supplemental material, the authors are encouraged to provide a short  
230 proof sketch to provide intuition.

231 **4. Experimental result reproducibility**

232 Question: Does the paper fully disclose all the information needed to reproduce the main ex-  
233 perimental results of the paper to the extent that it affects the main claims and/or conclusions  
234 of the paper (regardless of whether the code and data are provided or not)?

235 Answer: [Yes]

236 Justification: Methods specify study periods, preprocessing, inclusion criteria and all analysis  
237 hyperparameters (bootstrap and permutation counts, HAC lag, seed) needed to reproduce  
238 the main results from the paper text alone; code and data will be released after review.

239 Guidelines:

- 240 • The answer NA means that the paper does not include experiments.  
241 • If the paper includes experiments, a No answer to this question will not be perceived  
242 well by the reviewers: Making the paper reproducible is important.  
243 • If the contribution is a dataset and/or model, the authors should describe the steps taken  
244 to make their results reproducible or verifiable.  
245 • We recognize that reproducibility may be tricky in some cases, in which case authors  
246 are welcome to describe the particular way they provide for reproducibility. In the case  
247 of closed-source models, it may be that access to the model is limited in some way  
248 (e.g., to registered users), but it should be possible for other researchers to have some  
249 path to reproducing or verifying the results.

250 **5. Open access to data and code**

251 Question: Does the paper provide open access to the data and code, with sufficient instruc-  
252 tions to faithfully reproduce the main experimental results, as described in supplemental  
253 material?

254 Answer: [Yes]

255 Justification: Code and anonymized data will be released with the repository after review; it  
256 will include step-by-step instructions. Submission hides links to preserve anonymity.

257 Guidelines:

- 258 • The answer NA means that paper does not include experiments requiring code.  
259 • Please see the Agents4Science code and data submission guidelines on the conference  
260 website for more details.  
261 • While we encourage the release of code and data, we understand that this might not be  
262 possible, so “No” is an acceptable answer. Papers cannot be rejected simply for not  
263 including code, unless this is central to the contribution (e.g., for a new open-source  
264 benchmark).  
265 • The instructions should contain the exact command and environment needed to run to  
266 reproduce the results.  
267 • At submission time, to preserve anonymity, the authors should release anonymized  
268 versions (if applicable).

269 **6. Experimental setting/details**

270 Question: Does the paper specify all the training and test details (e.g., data splits, hyper-  
271 parameters, how they were chosen, type of optimizer, etc.) necessary to understand the  
272 results?

273 Answer: [Yes]

274 Justification: Methods describe data periods, preprocessing, aggregation, models and tests;  
275 environment details are documented and will be released after review.

276 Guidelines:

- 277 • The answer NA means that the paper does not include experiments.
- 278 • The experimental setting should be presented in the core of the paper to a level of detail  
279 that is necessary to appreciate the results and make sense of them.
- 280 • The full details can be provided either with the code, in appendix, or as supplemental  
281 material.

## 282 7. Experiment statistical significance

283 Question: Does the paper report error bars suitably and correctly defined or other appropriate  
284 information about the statistical significance of the experiments?

285 Answer: [\[Yes\]](#)

286 Justification: We report effect sizes with 95% bootstrap CIs, permutation p-values and  
287 HAC-robust SEs where applicable.

288 Guidelines:

- 289 • The answer NA means that the paper does not include experiments.
- 290 • The authors should answer "Yes" if the results are accompanied by error bars, confi-  
291 dence intervals, or statistical significance tests, at least for the experiments that support  
292 the main claims of the paper.
- 293 • The factors of variability that the error bars are capturing should be clearly stated  
294 (for example, train/test split, initialization, or overall run with given experimental  
295 conditions).

## 296 8. Experiments compute resources

297 Question: For each experiment, does the paper provide sufficient information on the com-  
298 puter resources (type of compute workers, memory, time of execution) needed to reproduce  
299 the experiments?

300 Answer: [\[Yes\]](#)

301 Justification: A CPU-only run completes in under a minute on a laptop; environment and  
302 exact commands are documented and will be released after review.

303 Guidelines:

- 304 • The answer NA means that the paper does not include experiments.
- 305 • The paper should indicate the type of compute workers CPU or GPU, internal cluster,  
306 or cloud provider, including relevant memory and storage.
- 307 • The paper should provide the amount of compute required for each of the individual  
308 experimental runs as well as estimate the total compute.

## 309 9. Code of ethics

310 Question: Does the research conducted in the paper conform, in every respect, with the  
311 Agents4Science Code of Ethics (see conference website)?

312 Answer: [\[Yes\]](#)

313 Justification: Study uses anonymized self-tracking data with consent; Responsible AI  
314 Statement documents AI roles; no sensitive identifiers included.

315 Guidelines:

- 316 • The answer NA means that the authors have not reviewed the Agents4Science Code of  
317 Ethics.
- 318 • If the authors answer No, they should explain the special circumstances that require a  
319 deviation from the Code of Ethics.

## 320 10. Broader impacts

321 Question: Does the paper discuss both potential positive societal impacts and negative  
322 societal impacts of the work performed?

323 Answer: [\[Yes\]](#)

324 Justification: Broader Impact section notes benefits of N-of-1 transparency and cautions  
325 about overgeneralization and privacy.

326 Guidelines:

- 327 • The answer NA means that there is no societal impact of the work performed.  
328 • If the authors answer NA or No, they should explain why their work has no societal  
329 impact or why the paper does not address societal impact.  
330 • Examples of negative societal impacts include potential malicious or unintended uses  
331 (e.g., disinformation, generating fake profiles, surveillance), fairness considerations,  
332 privacy considerations, and security considerations.  
333 • If there are negative societal impacts, the authors could also discuss possible mitigation  
334 strategies.